Administration of monoclonal antibodies to Ia antigens partially suppresses Theiler's virus-induced demyelination, suggesting mediation by immune cells carrying Ia class II molecules.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating in a viral demyelination model; leaves open whether Ia-targeted therapy merits human investigation.
In vivo administration of monoclonal antibody reactive with major histocompatibility complex-encoded Ia molecules (I-As) partially suppressed inflammation and demyelination in the spinal cord of SJL/J (H-2s) mice persistently infected with Theiler's murine encephalomyelitis virus. Demyelination was decreased if antibody was given at the time of virus inoculation or after inflammation had been established in the spinal cord. The decrease in demyelination was independent of isolation of infectious virus from the CNS or of serum titers of immunoglobulin to purified viral antigen. Thus, Theiler's virus-induced demyelination is mediated, in part, by immune cells that carry Ia class II molecules.
No takes yet. Share an insight, caveat, or question.
Rodriguez et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: